Kadant operates a razor-and-blades business model, selling capital equipment alongside recurring aftermarket parts, which supports margins above 20% and long-term growth. Despite its diverse product lineup, the company's focus on industrial equipment and consumables unifies its offerings. This recurring revenue stream from aftermarket parts is key to Kadant's financial strength and explains why its stock appears undervalued at current market multiples. The article emphasizes understanding the business model to appreciate the company's value.
Kadant's razor-and-blades business model is the subject, with Pluang's Industrials sector data providing market context. As of Sep 27, 2026 16:02 WIB, 56 of 93 Industrials stocks rose while 37 fell. Notably, Enovix Corporation (ENVX) traded at USD 2.87 with a 3.04% decline and a typical hold time of 10 days, contrasting with W W Grainger Inc (GWW) at USD 1,243.07 down 2.84% and a longer hold time of 21 days, while Southwest Airlines Co (LUV) rose 2.72% to USD 42.68 with a much longer hold time of 64 days and a Pluang order activity of 100% sell.
Bitcoin held steady around $84,626, marking a 0.84% daily gain and a 43.5% rise this quarter, its best Q3 since 2017. U.S. spot Bitcoin ETFs attracted $2.4 billion last week, the largest weekly inflow in nearly a year, signaling strong institutional ...
Solana (SOL) has risen above $120 for the first time since January, gaining about 8% in a week amid strong market momentum. This surge follows the deployment of the Alpenglow network upgrade on devnet, which aims to drastically reduce transaction fin...
Chainlink has seen large holders add over 2.5 million LINK tokens in the past 10 days, signaling strong confidence and potential for price gains. Nearly 1,500 new LINK addresses are created daily, indicating steady network growth and adoption. The to...
Large holders, or whales, have purchased over 1.14 billion Dogecoin tokens worth $112 million in the past 96 hours as the price struggles to break the key resistance around $0.10. This aggressive accumulation during price dips has been a recurring pa...
Annexon is focusing its clinical trials on maintaining functional outcomes for patients with geographic atrophy and Guillain-Barré syndrome, aiming to show real-world benefits like vision and physical recovery preservation. The ARCHER II trial now ta...
